Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
IN-VIVO RETARGETING OF T-CELL EFFECTOR FUNCTION BY RECOMBINANT BISPECIFIC SINGLE-CHAIN FV (ANTI-CD3 X ANTIIDIOTYPE) INDUCES LONG-TERM SURVIVAL IN THE MURINE BCL1 LYMPHOMA MODEL
Autore:
DEJONGE J; HEIRMAN C; DEVEERMAN M; VANMEIRVENNE S; MOSER M; LEO O; THIELEMANS K;
Indirizzi:
FREE UNIV BRUSSELS,SCH MED,LAB PHYSIOL IMMUNOL,LAARBEEKLAAN 103-E B-1090 BRUSSELS BELGIUM FREE UNIV BRUSSELS,SCH MED,LAB PHYSIOL IMMUNOL B-1090 BRUSSELS BELGIUM FREE UNIV BRUSSELS,PHYSIOL ANIM LAB RHODE ST GENESE BELGIUM
Titolo Testata:
The Journal of immunology (1950)
fascicolo: 3, volume: 161, anno: 1998,
pagine: 1454 - 1461
SICI:
0022-1767(1998)161:3<1454:IROTEF>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
HIGH-LEVEL EXPRESSION; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; HUMAN TUMORS; LYMPHOCYTES; FRAGMENTS; INTERLEUKIN-12; CYTOTOXICITY; EFFICIENT; CARCINOMA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
51
Recensione:
Indirizzi per estratti:
Citazione:
J. Dejonge et al., "IN-VIVO RETARGETING OF T-CELL EFFECTOR FUNCTION BY RECOMBINANT BISPECIFIC SINGLE-CHAIN FV (ANTI-CD3 X ANTIIDIOTYPE) INDUCES LONG-TERM SURVIVAL IN THE MURINE BCL1 LYMPHOMA MODEL", The Journal of immunology (1950), 161(3), 1998, pp. 1454-1461

Abstract

As demonstrated in several preclinical models, bispecific Abs are attractive immunotherapeutic agents for tumor treatment. We have previously reported that a bacterially produced anti-CD3 x antitumor bispecific single chain variable fragment of Ab fragment (BsscFv), which is capable of retargeting CTLs toward BCL1 tumor cells, exhibits antitumor activity in vitro. To further facilitate BsscFv production, the coding sequence was subcloned in a eukaryotic expression vector and introduced into Chinese hamster ovary cells for large-scale production. In thisreport, we have determined the serum stability and the clearance ratefrom the circulation of BsscFv, Most important, we prove here the therapeutic value of BsscFv in the treatment of BCL1 lymphoma, a murine model for human non-Hodgkin's lymphoma. Tumor-bearing mice that were treated with rscFv in combination with staphylococcal enterotoxin B superantigen, human rIL-2, or murine rIL-12 shelved long-term survival, whereas untreated mice all died. This is the first report of the successful in vivo use of BsscFv as an immunotherapeutic agent. Furthermore, long-term survival was the result of complete tumor removal and was not due to the induction of dormancy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/07/20 alle ore 07:58:19